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Background: Increased plasma C-reactive protein (CRP) is associated with the occurrence and severity of acute myocardial infarction. Although 
the liver is the most common source of circulating CRP, we examined whether CRP can be generated in vascular endothelial cells (ECs) in exposure 
to electronegative low-density lipoprotein (LDL), which has been shown to be atherogenic to ECs. Because CRP is a ligand for lectin-like oxidized LDL 
receptor-1 (LOX-1), we also examined the role of LOX-1 in CRP induction.
Methods: Plasma LDL samples isolated from asymptomatic hypercholesterolemic (HC; LDL cholesterol [LDL-C]=155±7 mg/dL, n=25) and 
normocholesterolemic (NC, LDL-C=98±9 mg/dL, n=12, P=0.006) individuals were resolved into 5 subfractions, L1-L5. The most (L5) and the least 
(L1) electronegative subfractions were compared for their ability to induce CRP expression in cultured human aortic ECs (HAECs).
Results: The L5/LDL% and plasma L5 concentration ([L5]: L5/LDL% x LDL-C) in HC and NC groups were 12.5±2.1% vs. 6.6±1.7% (P=0.04) and 
17.2±2.7 mg/dL vs. 6.8±2.1 mg/dL (P=0.005), respectively. L5 upregulated CRP in a concentration (10-100 μg/mL) and time (1 minute to 24 
hours) dependent manner, up to a 3-fold increase (P<0.01). L1 had no effect. L1, which is internalized through normal LDL receptor, became visible 
inside HAECS within 5 minutes when fluorescently labeled. The entry of L5, mediated by LOX-1, became apparent only after 30 minutes of contact. 
CRP induction, which was attenuated by neutralizing LOX-1, also manifested at 30 minutes. Also at 30 minutes, L5 but not L1 induced prominent 
production of reactive oxygen substances. In 6 HC individuals who consented to take atorvastatin 10 mg/day, [L5] decreased from 11.8±2.0 mg/
dL to 4.7±0.6 mg/dL (P=0.01), greatly reduced the ability of the plasma LDL to promote CRP synthesis. At 6 months, the effectiveness remained 
unchanged in 4 compliant patients, whereas both L5/LDL% and [L5] returned to the baseline levels in the 2 non-compliant patients.
Conclusions: L5 upregulates CRP through LOX-1 in vascular ECs. Because CRP is a ligand for LOX-1, this forms an L5/LOX-1/CRP cyclic 
mechanism in atherogenicity. Reducing plasma L5 disrupts this mechanism. 
